MW 494.1 Da, Purity >98%. Potent 5-lipoxygenase activating protein inhibitor (FLAP) (IC50 = 44 nM). Inhibits leukotriene biosynthesis (IC50 = 2.5 nM) in vitro and tumor activity in vivo. Displays PPARα antagonist activity. Orally active in vivo.
Images
Publications
Filter by
- Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme 45:227-2392019Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.Applications:Unspecified applicationReactive species:Unspecified reactive speciesYujie Huang,Hedong Lang,Ka Chen,Yong Zhang,Yanxiang Gao,Li Ran,Long Yi,Mantian Mi,Qianyong ZhangPubMed 31173696
- Molecular and cellular endocrinology 493:1104502019Role of adiponectin/peroxisome proliferator-activated receptor alpha signaling in human chorionic gonadotropin-induced estradiol synthesis in human luteinized granulosa cells.Applications:Unspecified applicationReactive species:Unspecified reactive speciesTao Tao et. al.PubMed 31116958
Key facts
- CAS number
- 118427-55-7
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 494.1 Da
- Molecular formula
- C27H33ClNNaO2S
- PubChem identifier
- 4519262
- Nature
- Synthetic
Target data
Alternative names
(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, 1,8-cineole 2-exo-monooxygenase, 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase, 3-oxoacyl-[acyl-carrier-protein] reductase, 3-oxoacyl-[acyl-carrier-protein] synthase, 41 kDa ubiquitin-specific protease, 5-LO, 5-LOX, 5-lipoxygenase, 5LPG, ALOX 5, Albendazole monooxygenase, Albendazole sulfoxidase, Arachidonate 5-lipoxygenase, Arachidonic acid 5 lipoxygenase, BDPLT14, BLM_HUMAN, BS, Bloom syndrome, Bloom syndrome RecQ helicase like, Bloom syndrome protein, CAMP GEFI, CGEF 1, CP2C9_HUMAN, CP33, CP34, CP3A4_HUMAN, CPC9, CYP2C, CYP2C10, CYP3, CYP3A, CYP3A3, CYP3A4, CYP5, CYP5A1, CYPIIC9, CYPIIIA3, CYPIIIA4, Cell cycle regulated protein kinase, Cytochrome P-450MP, Cytochrome P450 2C9, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 5A1, Cytochrome P450 HLp, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 NF-25, Cytochrome P450 PB-1, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 2, subfamily C, polypeptide 9, Cytochrome P450, family 5, subfamily A, polypeptide 1, Cytochrome P450-PCN1, Cytosolic NADP-isocitrate dehydrogenase, DINB protein, DINB1, DINP, DKFZp686C2056, DNA damage inducible protein b, DNA directed DNA polymerase beta, DNA helicase, DNA helicase RecQ like type 2, DNA helicase, RecQ like type 3, DNA pol beta, DNA polymerase beta, DNA polymerase beta subunit, DNA polymerase eta, DNA polymerase iota, DNA polymerase kappa, DNA replication inhibitor, DPOLB_HUMAN, Deubiquitinating enzyme 2, DinB homolog 1 (E. coli), EPA1, EPAC, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ESRL 1, ESRR A, Enoyl-[acyl-carrier-protein] reductase, Epac 1, Epididymis luminal protein 216, Epididymis secretory protein Li 26, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen-related receptor alpha, Estrra, Eta 2, Exchange factor directly activated by cAMP 1, Exchange protein directly activated by cAMP 1, Exonuclease WRN, FASN, FAS_HUMAN, FLJ16395, FLJ21978, FLJ52771, Fatty acid synthase, GEMI_HUMAN, GHOSAL, GLP-1 receptor, GLP1R_HUMAN, GMNN, Geminin, Geminin DNA replication inhibitor, Glucagon-like peptide 1 receptor, Glucocorticoid inducible P450, HEL-216, HEL-S-26, HGNC 12791, HLP, ICDH, IDCD, IDH, IDH1, IDHC_HUMAN, IDP, IDPC, Isocitrate dehydrogenase (NADP(+)) 1 cytosolic, Isocitrate dehydrogenase 1 (NADP+) soluble, Isocitrate dehydrogenase [NADP] cytoplasmic, LOG 5, LOX5_HUMAN, Leukotriene A4 synthase, MGC125976, MGC126616, MGC126680, MGC131618, MGC131620, MGC138331, MGC14367, MGC149605, MGC15706, MGC163204, MGC21410, MGC88320, Microsomal monooxygenase, NADP dependent isocitrate dehydrogenase cytosolic, NADP dependent isocitrate dehydrogenase peroxisomal, NADP(+)-specific ICDH, NF 25, NR3B1, Nifedipine oxidase, Nuclear receptor subfamily 3 group B member 1, OA 519, OTTHUMP00000016340, OTTHUMP00000020135, OTTHUMP00000039393, OTTHUMP00000225301, Oleoyl-[acyl-carrier-protein] hydrolase, Oxalosuccinate decarboxylase, P450 III steroid inducible, P450 MP, P450 PB 1, P450 PCN1, P450, family III, P450C3, P450IIC9, PICD, PLK, PLK1_HUMAN, POLH_HUMAN, POLI_HUMAN, POLK_HUMAN, POLQ, Platelet cytochrome P450 subfamily V, Pol B, Pol beta, Polo-like kinase 1, Polymerase (DNA directed) beta, Polymerase (DNA directed) iota, Polymerase (DNA directed) kappa, Quinine 3-monooxygenase, RAD 30B, RAD30, RAD30 homolog A, RAD30 homolog B, RAD30, S. cerevisiae, homolog of, RAD30A, RAD3OB, RAP guanine nucleotide exchange factor, RAP guanine nucleotide exchange factor 3, RAPGEF3, RECQ 2, RECQ like, RECQL 2, RECQL 3, RP3 369A17.3, Rap guanine nucleotide exchange factor (GEF) 3, Rap1 guanine nucleotide exchange factor directly activated by cAMP, RecQ protein-like 2, RecQ protein-like 3, RecQ-like type 2, RecQ-like type 3, RecQ3, S-mephenytoin 4-hydroxylase, SDR27X1, STPK 13, Serine/threonine-protein kinase 13, Serine/threonine-protein kinase PLK1, Short chain dehydrogenase/reductase family 27X member 1, Steroid hormone receptor ERR1, THAS_HUMAN, TS, TXA synthase, TXAS, TXS, Taurochenodeoxycholate 6-alpha-hydroxylase, Tbxas1, Thromboxane A synthase 1, Thromboxane A synthase 1 (platelet), Thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A), Thromboxane A synthase 1 platelet cytochrome P450 subfamily V, Thromboxane-A synthase, UBP-t, UBP2_HUMAN, UBP41, USP9, Ubiquitin carboxyl-terminal hydrolase 2, Ubiquitin specific protease 12, Ubiquitin specific protease, 41kD, Ubiquitin thioesterase 2, Ubiquitin thiolesterase 2, Ubiquitin-specific protease 9, Ubiquitin-specific-processing protease 2, Ubiquitin-specific-processing protease testis, WRN_HUMAN, Werner syndrome ATP-dependent helicase, Werner syndrome helicase, Werner syndrome protein, Werner syndrome, RecQ helicase like, XP V, Xenobiotic monooxygenase, Xeroderma pigmentosum variant type protein, [Acyl-carrier-protein] S acetyltransferase, [Acyl-carrier-protein] S malonyltransferase, arachidonic 5-lipoxygenase alpha-10 isoform, arachidonic 5-lipoxygenase delta-10-13 isoform, arachidonic 5-lipoxygenase delta-13 isoform, arachidonic 5-lipoxygenase delta-p10 isoform, bcm910, cAMP regulated guanine nucleotide exchange factor I, cytochrome P-450 S-mephenytoin 4-hydroxylase, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, estrogen receptor related receptor alpha, flavoprotein-linked monooxygenase, hERR1, polymerase DNA directed eta, polymerase, DNA, kappa, type 2, ubiquitin specific peptidase 2
Recommended products
MW 494.1 Da, Purity >98%. Potent 5-lipoxygenase activating protein inhibitor (FLAP) (IC50 = 44 nM). Inhibits leukotriene biosynthesis (IC50 = 2.5 nM) in vitro and tumor activity in vivo. Displays PPARα antagonist activity. Orally active in vivo.
Key facts
- CAS number
- 118427-55-7
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 494.1 Da
- Molecular formula
- C27H33ClNNaO2S
- PubChem identifier
- 4519262
- Nature
- Synthetic
- Solubility
Soluble in DMSO to 50 mM.
- Biochemical name
- MK886 sodium
- Biological description
Potent 5-lipoxygenase activating protein inhibitor (FLAP) (IC50 = 44 nM). Inhibits leukotriene biosynthesis (IC50 = 2.5 nM) in vitro and tumor activity in vivo. Displays PPARα antagonist activity. Orally active in vivo.
- Canonical SMILES
- CC(C)C1=CC2=C(C=C1)N(C(=C2SC(C)(C)C)CC(C)(C)C(=O)[O-])CC3=CC=C(C=C3)Cl.[Na+]
- InChI
- InChI=1S/C27H34ClNO2S.Na/c1-17(2)19-10-13-22-21(14-19)24(32-26(3,4)5)23(15-27(6,7)25(30)31)29(22)16-18-8-11-20(28)12-9-18;/h8-14,17H,15-16H2,1-7H3,(H,30,31);/q;+1/p-1
- InChIKey
- CBNCIYNCWVGEKJ-UHFFFAOYSA-M
- IUPAC name
- sodium;3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoate
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- Ambient
- Appropriate long-term storage conditions
- Ambient
- Storage information
- The product can be stored for up to 12 months
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
The Werner's syndrome helicase (WRN) is a RecQ DNA helicase associated with the Werner's syndrome often linked to premature aging. It weighs approximately 143 kDa and is expressed in the nucleus of various human cell types including fibroblasts and lymphocytes. DNA Polymerase beta is involved in base excision repair and has a molecular mass of about 39 kDa predominantly found in the nucleus. Bloom's syndrome protein (BLM) also belongs to the RecQ helicase family and is involved in maintaining genomic stability. PLK1 (Polo-like kinase 1) regulates various stages of mitosis and is a serine/threonine-protein kinase. DNA Polymerase iota (POLI) contributes to translesion synthesis a process of DNA repair while Cytochrome P450 3A4 (CYP3A4) participates in drug metabolism. Geminin prevents DNA replication during the cell cycle. Fatty acid synthase catalyzes the synthesis of long-chain fatty acids and CYP2C9 is involved in metabolizing xenobiotics. DNA Polymerase Kappa (POLK) aids in translesion synthesis and Estrogen Related Receptor alpha influences mitochondrial function. GLP-1R (glucagon-like peptide-1 receptor) involves in glucose homeostasis Thromboxane synthase is an enzyme in eicosanoid synthesis while DNA polymerase eta (POLH) aids in bypassing DNA lesions. Epac1 is a cAMP-regulated guanine nucleotide exchange factor and 5-Lipoxygenase (5-LO) generates leukotrienes pivotal in inflammation often being the focus of lipoxygenase inhibitors. IDH1 is an enzyme in the citric acid cycle and USP2 is a deubiquitinating enzyme.
- Biological function summary
These targets serve diverse roles in maintaining cellular function and genetic integrity. WRN BLM POLK and POLH contribute to DNA repair and stability within the cell important in safeguarding against genomic instability. These proteins participate in complexes like the DNA damage response machinery ensuring efficient repair of damaged DNA. Enzymes like CYP3A4 and CYP2C9 in the cytochrome P450 family are essential in drug metabolism and detoxification processes expressed mainly in the liver. Fatty acid synthase plays a role in lipid biosynthesis essential for cellular membrane formation and energy storage. Furthermore GLP-1R and Estrogen Related Receptor alpha influence metabolic regulation emphasizing their importance in glucose metabolism and mitochondrial functions respectively.
- Pathways
These targets integrate into key biological systems and processes. WRN BLM and POLK integrate into the DNA damage response pathway maintaining genomic integrity alongside partners like RAD51. FAT synthase and CYP enzymes participate in metabolic pathways impacting lipid biosynthesis and drug metabolism pathways respectively. GLP-1R is actively involved in the incretin signaling pathway modulating insulin secretion and glucose homeostasis. Meanwhile Thromboxane synthase and 5-LO enzymes are components of the eicosanoid synthesis pathway influencing inflammatory responses. Epac1 engages in the cAMP signaling pathway affecting various cellular processes including cell adhesion and secretion dynamics.
- Associated diseases and disorders
Dysfunctions in these targets often associate with several pathologies. Mutations in WRN can lead to Werner's syndrome characterized by symptoms of premature aging and genomic instability. Bloom's syndrome linked to mutations in BLM results in increased cancer risk due to DNA repair defects. Abnormal CYP3A4 activity may affect drug clearance leading to adverse drug reactions or ineffective therapies. Disruption in GLP-1R signaling has connections to diabetes mellitus due to impaired insulin regulation. Altered fatty acid synthase activity associates with obesity and cancer given its role in lipid synthesis. Lipoxygenase inhibitors often target 5-LO due to its involvement in inflammatory diseases such as asthma. Collectively the proper function of these biological targets remains critical for preserving health and preventing disease progression.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Chemical Structure - MK886, Lipoxygenase inhibitor (ab141140)
2D chemical structure image of ab141140, MK886, Lipoxygenase inhibitor
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com